144 related articles for article (PubMed ID: 11676354)
1. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.
Johansson JE; Wersäll P; Brandberg Y; Andersson SO; Nordström L;
Scand J Urol Nephrol; 2001 Sep; 35(4):288-94. PubMed ID: 11676354
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin treatment in metastatic breast cancer--effects on Hb, quality of life and need for transfusion.
Olsson AM; Svensson JH; Sundström J; Bergström S; Edekling T; Carlsson G; Hansen J; Svensson B; Albertsson M
Acta Oncol; 2002; 41(6):517-24. PubMed ID: 12546524
[TBL] [Abstract][Full Text] [Related]
3. Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
Bogdanos J; Karamanolakis D; Milathianakis K; Repousis P; Chloraki-Bobota A; Majed H; Pagalou-Thoua E; Tsintavis A; Koutsilieris M
Anticancer Res; 2004; 24(3b):1957-61. PubMed ID: 15274384
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.
Morishima Y; Ogura M; Yoneda S; Sakai H; Tobinai K; Nishiwaki Y; Minami H; Hotta T; Ezaki K; Ohe Y; Yokoyama A; Tsuboi M; Mori K; Watanabe K; Ohashi Y; Hirashima K; Saijo N;
Jpn J Clin Oncol; 2006 Oct; 36(10):655-61. PubMed ID: 16987908
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
6. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.
Mantovani G; Ghiani M; Curreli L; Maccio A; Massa D; Succu G; Lai P; Massa E; Mudu MC; Astara G
Oncol Rep; 1999; 6(2):421-6. PubMed ID: 10023014
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.
Osterborg A; Brandberg Y; Molostova V; Iosava G; Abdulkadyrov K; Hedenus M; Messinger D;
J Clin Oncol; 2002 May; 20(10):2486-94. PubMed ID: 12011126
[TBL] [Abstract][Full Text] [Related]
9. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
10. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z; DeSantis ER
Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
[TBL] [Abstract][Full Text] [Related]
11. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.
Glimelius B; Linné T; Hoffman K; Larsson L; Svensson JH; Näsman P; Svensson B; Helmers C
J Clin Oncol; 1998 Feb; 16(2):434-40. PubMed ID: 9469326
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
Ludwig H; Sundal E; Pecherstorfer M; Leitgeb C; Bauernhofer T; Beinhauer A; Samonigg H; Kappeler AW; Fritz E
Cancer; 1995 Dec; 76(11):2319-29. PubMed ID: 8635038
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.
Miller CB; Platanias LC; Mills SR; Zahurak ML; Ratain MJ; Ettinger DS; Jones RJ
J Natl Cancer Inst; 1992 Jan; 84(2):98-103. PubMed ID: 1735886
[TBL] [Abstract][Full Text] [Related]
15. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group.
Maier RF; Obladen M; Scigalla P; Linderkamp O; Duc G; Hieronimi G; Halliday HL; Versmold HT; Moriette G; Jorch G
N Engl J Med; 1994 Apr; 330(17):1173-8. PubMed ID: 8139627
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
Provenzano R; Garcia-Mayol L; Suchinda P; Von Hartitzsch B; Woollen SB; Zabaneh R; Fink JC;
Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
[TBL] [Abstract][Full Text] [Related]
17. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
18. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
19. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
